The global market for monoclonal antibody therapy was valued at USD 195.63 billion in 2023. The market is estimated to grow at a CAGR of 16.24% from 2023 to 2028 and will be worth USD 408.79 billion by 2028.
Y-O-Y growth in the prevalence of cancer and chronic diseases is one of the significant factors driving the global monoclonal antibody therapy market growth.
These diseases have led to an increasing demand for biologics, which generates a demand for monoclonal antibodies. Furthermore, the growing dynamics of genetic research and development and the emergence of technologically advanced genetic platforms, such as next-generation sequencing/ stem cell technology, have contributed significantly to the market. In addition, the affordability of the research technology required to develop mAbs has also contributed to the growth of the global monoclonal antibody therapy market.
The homogeneity of the mAbs also makes them suitable for experimental procedures, as they can facilitate the production of identical antibodies. Thus increasing their demand in the healthcare sector. Other factors positively impacting the market are increased patient and clinician awareness of mAb therapy, the introduction of better products, increasing adoption of antibodies in sensitive markets, and rapid approval by regulatory authorities for innovative monoclonal antibody therapies. The increased production and identification of specific antibodies against particular antigens results in unique products in laboratories. The growing prevalence of cost-effective mAbs is driving the growth of the global monoclonal antibody therapy market.
The monoclonal antibody therapy market is gaining opportunities using biological therapy to treat different types of chronic diseases such as rheumatoid arthritis, cancer, Crohn's disease, osteoporosis, systemic lupus erythematosus, psoriasis, etc. This disease often needs customized treatment modalities. The affirmative indication of the controlling establishments for the entry of biosimilars of the predominant mAb therapies further promotes the growth of the market, the increase in autoimmune disease cases is expected to generate the maximum opportunity for the market growth of the monoclonal antibody therapy market over the forecast period.
Some problems that arise in the manufacture of mAbs include a cost-effective procedure and susceptibility to contamination. In addition, production requires additional cell culture and purification procedures to produce mAbs successfully. Furthermore, other factors, such as the availability of alternative treatment methods and natural remedies, are gaining popularity worldwide. Therefore, it is expected to negatively impact the monoclonal antibody drug market growth during the forecast period.
A disadvantage of drugs formulated from mAb is that they are precise and have limited purposes. This is because they interact with cells and do not penetrate them. To some extent, this has hampered the monoclonal antibody market. Another difficulty in using mAbs is that they must be injected into the body and hence are disliked by patients.
COVID-19 Impact on the Global Monoclonal Antibody Therapy Market:
The COVID-19 pandemic significantly impacts the monoclonal antibody therapy market growth. However, the restrictive containment measures involving social distancing, remote working, and business closures have decreased market revenues. A growing number of government initiatives and funding for clinical trials of drugs, which can be used in the treatment of COVID-19, are expected to support market growth, which is expected to reach between USD 80- 100 billion in 2020 &2021, growing at a CAGR by 12%. This is mainly due to the increase in R&D associated with COVID-19 vaccination.
Market Size Available
2022 to 2028
2023 to 2028
By Type, Application, Distribution channel, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global monoclonal antibody therapy market has been segmented and sub-segmented based on Type, Application, Distribution channel, and Region.
Global Monoclonal Antibody Therapy Market - By Type:
The human mAb segment held the majority share of the monoclonal antibody therapy market. The segment growth is driven by growing demand and higher sales for Humira. Furthermore, the introduction of Adalimumab biosimilars is projected to boost sector growth from 2023 to 2028. Amgen, for example, announced the introduction of Amgevita, a biosimilar of adalimumab, in Europe in October 2018.
Global Monoclonal Antibody Therapy Market -By Application:
The cancer segment augmented the largest share of the market and is expected to continue its growth during the forecast period. The segment growth is fuelled by the increased incidence of rheumatoid arthritis, the quick adoption of biological therapies, and new autoimmune illness. In addition, other factors, such as favorable reimbursement policies, the proliferation of chronic diseases, and the adoption of advanced technology, are driving market growth.
Global Monoclonal Antibody Therapy Market -By Distribution Channel:
Hospital Pharmacy Retail Pharmacy
The hospital pharmacy generates significant revenue. The factors such as active government interventions for chronic diseases, improving healthcare expenditure, and favorable reimbursement policies across the countries fuel the market growth. On the other hand, the availability of advanced infrastructure, increasing prevalence of cancer cases, and improving focus by the manufacturers across the regions are expanding the hospital pharmacy segment growth.
Global Monoclonal Antibody Therapy Market – By Region:
Middle East and Africa
Based on region, North America occupies a dominant position in the market due to well-established healthcare infrastructure, the government's emphasis on infection control and management, and a higher prevalence of lifestyle-related diseases. As a result, the United States is expected to control the North American market. In addition, the U.S market will continue on its upward trajectory due to increased government funding for cancer research and technology development.
According to American Cancer Society estimates for the year 2020 in the United States, approximately 1,855,950 new cancer cases and 606,550 cancer deaths have been estimated, which are expected to continue in the future by fueling the market demand. For example, the National Institute of Standards and Technology bio-fabrication initiative in the United States provides scientifically sound regulatory guidance to ensure the efficient and safe manufacture of protein therapies and to help biopharmaceutical manufacturers deliver high-quality protein drugs and low cost all over the world.
The European market will gain market revenues owing to government initiatives to enable profitable mAb production, which is expected to foster this sector's emergence during the forecast period.
In the future, Asia-Pacific is also expected to show tremendous growth due to the increased spending on research and development, high purchase rate, and growing patient awareness for the therapeutic use of mAbs. China has significant growth potential in the APAC region due to the favorable government initiatives supporting the research and treatment for mAbs applications and the increase in funded R&D projects for developing cheaper mAbs. For example, government donors such as the National Foundation of Natural Sciences and the National Basic Research Program of China provide financial support to companies and universities to conduct research and development on mAbs.
The LATAM market will also offer solid growth promises for the future.
KEY MARKET PLAYERS:
Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd are some of the dominating companies in the global monoclonal antibody therapy market.
RECENT MARKET DEVELOPMENTS:
In February 2019, AbCellera and Novartis teamed up with multiple goals to create an antibody and drug discovery platform and technology for treating neurodegenerative and clinically relevant diseases.
In January 2020, Daiichi Sankyo Company had a very successful product, ENHERTU, in the United States to its existing portfolio of monoclonal antibody therapies with accelerated approval from the Administration of the US FDA.
In March 2020, the World Health Organization launched the "Solidarity" trial, an initiative to search for any therapy to treat Covid-19 virus. This trial includes the trial of four therapies; remdesivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir, and lopinavir with ritonavir and interferon beta.
In July 2020, UCB announced a collaboration agreement with Roche to develop an antibody treatment for Alzheimer's disease. This has strengthened the company's product development capabilities through Roche's global presence in the field.
In September 2020, Eli Lilly and Company collaborated with Amgen to expand antibody production and supply capacity for COVID-19 therapies. This has helped the company continue distributing its products to the market amid the pandemic.
In February 2021, AstraZeneca, a pharmaceutical wonder, is conducting phase II medical experiments with Tezepelumab to cure atopic dermatitis.
The monoclonal antibody therapy market worldwide is estimated to value USD 165.72 million in 2022.
This report includes the COVID-19 impact on the monoclonal antibody therapy market.
Geographically, the North American region led the monoclonal antibody therapy market in 2022.
Abbvie, F.Hoffmann-la Roche and Merck are a few of the major players in the global monoclonal antibody therapy market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]